🏢 官网IRRVTYDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 20:00:00(美东 08:00)·⟳ 抓取 20:07:40回填·⚡ 决策 10-13 20:08:37·14.2 天前
Revvity宣布CEO将出席11月Jefferies与12月Evercore医疗健康投资者会议，属例行日程公告无新增基本面信息
这是一份标准的投资者会议出席公告（conference appearance notice），炉边谈话内容为常规战略更新，不含业绩、指引、订单等任何增量事实；会议在一个多月后才举行，当下无催化、无预期差，不构成交易机会。
📄 原文RVTY↗ 原文
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor…
不做 Revvity, Inc.（RVTY.US）
例行投资者会议出席公告，无业绩、指引、订单等任何增量事实，会议在一个多月后举行，当下无催化与预期差，不存在可交易edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Revvity官方宣布CEO将出席11月和12月两场医疗投资者会议，属例行IR日程通告，无新增基本面信息或surprise，不具备交易edge，建议不做。
🔎 新鲜度:最早出现 2026-10-13 · 扩散 low · price-in 风险 low ↗
主要风险
- 真正的潜在催化要等到11月17日/12月2日会议当天管理层表态，本公告本身不提供任何方向性信息
先例如何影响了这次决策
对本次决策的影响:未据此设置任何交易；此类公告不具备校准tp/sl的基础
方向:无值得统计的同类事件：例行投资者会议出席公告属于无增量信息的IR日程，市场通常不产生系统性反应
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 9 ms
{"result": "search_processed_events:agent query=`revvity investor conference presentation jefferies evercore 2026 | rvty prahlad singh fireside chat november december 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 1,692 字
WALTHAM, Mass.--(BUSINESS WIRE)--
Revvity, Inc.
(NYSE: RVTY), today announced it will present at the following investor conferences:
2026 Jefferies Global Healthcare Conference
Tuesday, November 17, 2026
8:00 a.m. GMT – Prahlad Singh, president and chief executive officer
9th Annual Evercore Healthcare Conference
Wednesday, December 2, 2026
9:10 a.m. ET – Prahlad Singh
Attendees will receive an update on the Company and its strategic priorities during fireside chats.
Live audio webcasts will be available on the
Events
section of the Company’s website. Replays of the presentations will be posted on the
Revvity Investor Relations website
after the events and will be available for at least 30 days.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our
Newsroom
,
LinkedIn
,
X
,
YouTube
,
Facebook
and
Instagram
.
Investor Relations
Steve Willoughby
steve.willoughby@revvity.com
Media Relations
Chet Murray
(781) 462-5126
chet.murray@revvity.com
Source: Revvity
Revvity, Inc.
(NYSE: RVTY), today announced it will present at the following investor conferences:
2026 Jefferies Global Healthcare Conference
Tuesday, November 17, 2026
8:00 a.m. GMT – Prahlad Singh, president and chief executive officer
9th Annual Evercore Healthcare Conference
Wednesday, December 2, 2026
9:10 a.m. ET – Prahlad Singh
Attendees will receive an update on the Company and its strategic priorities during fireside chats.
Live audio webcasts will be available on the
Events
section of the Company’s website. Replays of the presentations will be posted on the
Revvity Investor Relations website
after the events and will be available for at least 30 days.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our
Newsroom
,
,
X
,
YouTube
,
and
.
Investor Relations
Steve Willoughby
steve.willoughby@revvity.com
Media Relations
Chet Murray
(781) 462-5126
chet.murray@revvity.com
Source: Revvity
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
47bd6c7d3b· 2026-10-13 20:08 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前